$-0.10 EPS Expected for Oxford Immunotec Global PLC (OXFD)

October 2, 2018 - By Ash

Oxford Immunotec Global PLC (NASDAQ:OXFD) LogoInvestors sentiment increased to 1.5 in 2018 Q2. Its up 0.16, from 1.34 in 2018Q1. It is positive, as 5 investors sold Oxford Immunotec Global PLC shares while 21 reduced holdings. 13 funds opened positions while 26 raised stakes. 23.43 million shares or 0.26% more from 23.37 million shares in 2018Q1 were reported.
Deutsche National Bank Ag owns 61,101 shares. First Light Asset Mgmt Ltd Liability Corporation invested in 1.24M shares. United Automobile Association invested 0.01% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). C Gp Holdings A S holds 0.03% or 164,073 shares. State Street Corp has 412,760 shares. Citadel Advsrs Limited Liability Corporation has 79,778 shares. 89,763 are held by Morgan Stanley. California State Teachers Retirement reported 38,841 shares or 0% of all its holdings. Manufacturers Life Insurance The owns 20,314 shares or 0% of their US portfolio. 118,154 were reported by Jacobs Levy Equity Mngmt. Spark Ltd Liability Co holds 0.11% in Oxford Immunotec Global PLC (NASDAQ:OXFD) or 144,100 shares. Barclays Plc, United Kingdom-based fund reported 3,178 shares. Penn Mngmt has invested 0.25% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Bnp Paribas Arbitrage accumulated 797 shares. Goldman Sachs Group Inc holds 0% or 63,180 shares.

Since May 1, 2018, it had 0 insider buys, and 2 sales for $636,304 activity. On Tuesday, May 1 SANDBERG RICHARD A sold $38,304 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) or 3,000 shares.

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $-0.10 EPS on October, 30.They anticipate $0.14 EPS change or 58.33 % from last quarter’s $-0.24 EPS. After having $-0.25 EPS previously, Oxford Immunotec Global PLC’s analysts see -60.00 % EPS growth. The stock increased 2.97% or $0.49 during the last trading session, reaching $16.99. About 85,122 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 1.09% since October 2, 2017 and is uptrending. It has underperformed by 14.53% the S&P500.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $441.19 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

More recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Streetinsider.com which released: “Quest Diagnostics (DGX) to Acquire US Laboratory Services Business of Oxford Immunotec” on September 25, 2018. Also Benzinga.com published the news titled: “The Daily Biotech Pulse: Verastem’s Chinese Duvelisib Licensing Deal, Aldeyra’s Positive Dry Eye Disease Drug Trial” on September 26, 2018. Benzinga.com‘s news article titled: “41 Stocks Moving In Tuesday’s Mid-Day Session” with publication date: September 25, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>